Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
When you read a news headline about a dementia breakthrough or a promising new treatment, your first instinct might be to hope—or to share it with a loved one. But before that headline shapes your decisions about care, you need to ask critical questions about the study behind it. The quality of dementia research varies dramatically, and many published studies contain methodological gaps that make their conclusions unreliable for patient care. Understanding what to ask about a study’s design, funding, sample size, and statistical reporting is the difference between identifying a genuine advance and chasing a result that won’t hold up in real-world practice. The stakes of poor research interpretation are especially high in dementia.
Families and patients often feel desperate for hope after a diagnosis, and researchers understand this. Yet desperation can cloud judgment—both for readers and, occasionally, for researchers themselves. A study showing that a supplement improved memory in 50 people may sound promising until you learn that half the participants dropped out mid-trial, that the study lasted only six weeks, and that the company making the supplement funded the research. These details matter enormously. This article walks you through the essential questions you should ask about every dementia study you encounter, from the methods used to measure cognitive decline to the financial interests behind the research. By the end, you’ll know what signals quality and what raises red flags.
Table of Contents
- Is the Sample Size Large Enough, and Was It Reported?
- Did the Study Measure What It Actually Claims to Measure?
- Does the Study Clearly State Its Causal Goal?
- Who Paid for the Study, and Did Money Influence the Results?
- Are the Study’s Limitations Honestly Acknowledged?
- Does the Study Account for How Dementia Naturally Progresses?
- How Will You Apply This Knowledge Going Forward?
- Conclusion
Is the Sample Size Large Enough, and Was It Reported?
One of the most overlooked problems in dementia research is that most studies don’t actually report whether their sample size was sufficient. Only 42% of placebo-controlled trials for dementia reported sample size calculations, and only 11% of head-to-head trials (comparing two active treatments) did so. This is a major red flag. A proper sample size calculation determines in advance how many participants a study needs to detect a meaningful treatment effect—without this, a study might recruit 30 people and claim success, when 300 would have been necessary to reach reliable conclusions. But here’s where the plot thickens: large sample size alone doesn’t guarantee a good study. Research examining trials with larger-than-required samples found that 72% reported statistically significant treatment effects, yet only 15% of those effects were clinically meaningful—meaning they wouldn’t noticeably change how a patient feels or functions.
A drug might shrink a cognitive decline score by a few points (statistically significant) without improving a person’s ability to remember a grandchild’s name or manage daily tasks (clinically meaningful). You need to ask not just whether a study is large, but whether its reported effect size actually matters in real life. Another critical detail is participant dropout, or attrition. Dementia studies often experience attrition rates as high as 26%, with some participants dropping out due to disease progression, moving away, or side effects. When a quarter of your participants vanish midway through, the remaining group may look systematically different from those who left—they might be healthier, more compliant, or more motivated. This selective survival bias can completely invalidate results.
Did the Study Measure What It Actually Claims to Measure?
Dementia research relies on standardized tests—things like cognitive screening scores, neuropsychological assessments, and biomarkers measured in blood or cerebrospinal fluid. But not all studies clearly define which tests they used, validate those tests, or report measurement error. When you read that a study found a 30% improvement in memory, you need to ask: Which specific test measured memory? Is that test validated in the population being studied? How much does that test naturally fluctuate from day to day? Measurement uncertainty compounds over time in longitudinal studies—research that follows the same people for months or years. A study that follows participants for 6 months will have different measurement precision than one following them for 5 years. The longer the follow-up, the more opportunities for unrelated changes in health, medication, or life circumstances to affect outcomes.
A well-designed study explicitly considers whether its statistical model matches its timeline and is transparent about where uncertainty increases. Studies also need to account for competing events—outcomes that can mask treatment effects. In dementia research, one competing event is death. If a study is measuring whether a treatment slows cognitive decline, but 5% of the treatment group dies during follow-up while 2% of the placebo group does, death is a confounding variable. Some participants never get a chance to decline further because they die. Does the study account for this? Transparent reporting should specify whether participants who died were included in analyses and how.
Does the Study Clearly State Its Causal Goal?
A critical mistake readers make is assuming any study is trying to prove that one thing causes another. But studies come in several flavors: they might describe associations (drug A is more common in people with dementia), show correlations (people taking supplement B also exercise more), or claim causation (drug C directly slows cognitive decline). The difference is enormous, but it requires careful reading to spot. Here’s a practical example: a study might find that people who drink more coffee have lower dementia rates. That sounds like coffee is protective. But the study is likely observational—researchers watched people over time and noticed this pattern. An observational study cannot prove causation because people who drink more coffee might also exercise more, have higher education, or better access to healthcare.
These unmeasured factors could explain the association. A randomized controlled trial, where some people are randomly assigned to drink coffee and others don’t, is far stronger evidence for causation. You need to ask: Is this an observational study, a case series, or a randomized trial? The design determines what conclusions are actually justified. risk of bias assessment tools help evaluate whether a study’s design reduces the potential for bias. The Cochrane Risk of Bias 2.0 tool is a gold standard, covering five key domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of reported results. Well-conducted studies will reference such tools and report independent assessments of their own risk of bias. If a study makes no mention of bias assessment or never discusses its limitations, skepticism is warranted.
Who Paid for the Study, and Did Money Influence the Results?
Conflict of interest disclosure is legally required in most medical journals, but disclosure is not the same as absence of conflict. Many dementia studies are funded by pharmaceutical companies developing new treatments, and studies with industry funding are significantly more likely to report favorable results than government-funded studies of the same treatments. This isn’t necessarily because researchers are intentionally dishonest—it’s because funding can influence which questions get asked, which analyses get run, and which results get published. When you encounter a dementia study, ask: Who funded it? Did the funder have any role in study design, data collection, analysis, interpretation, or manuscript preparation? Were authors paid as consultants or speakers for the funding company? Were there travel sponsorships? These details matter.
A pharmaceutical company funding a trial of its own drug creates obvious incentives to show a positive result. Government-funded studies (like those from the NIH or National Institute on Aging) generally have structural independence, but you should still verify that funders did not dictate data interpretation or suppress inconvenient findings. Transparency about funding goes beyond naming the source. The best studies specify whether the funder was blinded to outcome data, whether the funder participated in manuscript drafting, and whether the funder had the right to approve publication. An industry-funded study where the company had final approval on the manuscript is much riskier than one where researchers retained full control.
Are the Study’s Limitations Honestly Acknowledged?
One hallmark of quality research is authors who openly discuss what their study cannot prove. A small study of medication effects in people with mild cognitive impairment cannot tell you anything about effects in advanced dementia. A six-month study cannot speak to long-term safety. Yet many published studies overstate their findings in abstracts or press releases while burying limitations in a brief paragraph at the end. Read the study’s discussion and limitations section carefully.
Are the authors candid about sample size constraints, dropout rates, or generalizability issues? Do they acknowledge that their findings need replication? Or do they imply their results are definitive? Caution should intensify if a study makes sweeping claims about “revolutionizing” dementia care when the evidence is preliminary. Quality research is inherently humble about what it can and cannot show. Another red flag is selective reporting of results. Not all studies pre-register their analysis plans, but those that do are more trustworthy because pre-registration prevents researchers from running dozens of analyses and reporting only the positive ones. If a study tested 20 different outcomes and published results for the three that were significant, statistical probability alone guarantees some false positives. Ask whether the study was pre-registered, and if not, whether the reported findings align with the stated hypothesis or appear exploratory.
Does the Study Account for How Dementia Naturally Progresses?
Dementia is not static—cognitive decline follows trajectories that vary by dementia type, age, genetics, and other health conditions. A responsible study designs its timeline and analysis around these realities. Vascular dementia progresses differently than Alzheimer’s disease, which progresses differently than Lewy body dementia. A treatment that slows decline in one type might be ineffective or harmful in another, yet many studies enroll mixed groups without stratifying results by dementia type.
Similarly, participant age matters. Cognitive trajectories for people diagnosed at 55 differ from those diagnosed at 85. Studies should specify the age range of participants and report whether effects differ by age. If a study reports an average effect size across a group ranging from age 50 to 95, that average might be meaningless—the treatment could help older adults while harming younger ones, and an average would hide that crucial difference.
How Will You Apply This Knowledge Going Forward?
Reading dementia research critically is a skill you’ll use repeatedly. The next time you see a headline about a dementia treatment, you now have a framework: ask about sample size and dropout, scrutinize how outcomes were measured, verify the causal claims match the study design, check for funding conflicts, and read what the authors say about limitations. Scientific evidence is not binary—studies fall on a spectrum from weak to strong, and understanding that spectrum helps you separate hype from hope.
The landscape of dementia research is improving. Funders increasingly require pre-registration and transparency about conflicts of interest. Organizations like the 2025 NIH Alzheimer’s Disease and Related Dementias Research Progress Report push for methodological rigor and reproducibility. But not every study you encounter will meet these standards, so your critical eye is essential.
Conclusion
Every dementia study is a story told by particular people, with particular funding sources, particular methods, and particular limitations. Your job as a reader is not to be cynical, but to be discerning—to understand what evidence actually justifies, what it leaves open, and when it’s too early to change your care decisions.
The questions outlined in this article form a checklist you can apply to any study, from research about a drug to trials about lifestyle interventions. The best dementia research is transparent about what it found, how it found it, who paid for it, and what remains unknown. By asking these questions, you honor the researchers who conduct rigorous work while protecting yourself and your loved ones from overinterpreted results.
